Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade

Journal of Autoimmunity

Volumn 31, Issue 2, 2008, Pages 175-179

  Ingegnoli, Francesca ^a   Fantini, Flavio ^a   Favalli, Ennio Giulio ^a   Soldi, Amedeo ^a   Griffini, Samantha ^a   Galbiati, Valentina ^a   Meroni, Pier Luigi ^a   Cugno, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Coagulation; Infliximab; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; ITALY; MALE; MIDDLE AGED; THROMBIN; THROMBOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 50849086145     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.07.002     Document Type: Article

References (18)

1. Gabriel S.E. Epidemiology of the rheumatic diseases. In: Harris E.D., Ruddy S., and Sledge C.B. (Eds). Kelley's textbook of rheumatology. Vol 1. 6th ed. (2000), W B Saunders Company, Philadelphia 321-333
2. Maradit-Kremers H., Crowson C.S., Nicola P.J., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. A population-based cohort study. Arthritis Rheum 52 (2005) 402-411
3. McEntegart A., Capell H.A., Creran D., Rumley A., Woodward M., and Lowe G.D. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40 (2001) 640-644
4. Busso N., and Hamilton J.A. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 46 (2002) 2268-2279
5. Sebbag M., Moinard N., Auger I., Clavel C., Arnaud J., Nogueira L., et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 36 (2006) 2250-2263
6. van der Poll T., Buller H.R., Ten Cate H., Wortel C.H., Bauer K.A., van Deventer S.J., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322 (1990) 1622-1627
7. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
8. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
9. St. Clair W., Wagner C., Fasanmade A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
10. Bauer K.A., and Weitz J.I. Laboratory markers of coagulation and fibrinolysis. In: Colman R.W., Hirsh J., Marder V.J., Clowes A.W., and George J.N. (Eds). Hemostasis and thrombosis: basic principles and clinical practice (2001), JB Lippincott, Philadelphia 1113-1129
11. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
12. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163 (1999) 1521-1528
13. Felson D.T., Anderson J.J., Boers M., Bombardier C., Chernoff M., Fried B., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36 (1993) 729-740
14. Bauer K.A., ten Cate H., Barzegar S., Spriggs D.R., Sherman M.L., and Rosenberg R.D. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 74 (1989) 165-172
15. MacCallum P.K., Rudnicka A.R., Rumley A., Meade T.W., and Lowe G.D.O. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. Brit J Haematol 127 (2004) 448-450
16. Hurlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002) 2184-2187
17. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S., Kikuchi Y., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 128 (2005) 376-392
18. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454